中国肺癌杂志2012，Vol.15Issue(8)：494-498,5.DOI:10.3779/j.issn.1009-3419.2012.08.08
厄洛替尼致间质性肺病4例并文献复习
Four Cases of Interstitial Lung Disease Induced by Erlotinib and A Review of the Literatures
吴小玲 1高广辉 2任胜祥 2周彩存2
作者信息
- 1. 643000自贡,自贡市第一人民医院呼吸科
- 2. 200433上海,同济大学附属上海市肺科医院肿瘤科
- 折叠
摘要
Abstract
Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors which are used for non-small cell lung cancer. Although this class of agents is considered to be relatively safe, the most serious, but rare, adverse reaction is drug-associated interstitial lung disease (ILD). ILD induced by gefitinib been often described, but the ILD induced by erlotinib is relatively less well known. We here describle four cases of ILD related to erlotinib and review recent literatures to help physicians earlier alert erlotinib-induced ILD. It is important to carefully monitor pulmonary symptoms in all patients who are receiving erlotinib. Early diagnosis and timely intervention is critical in the treatment of drug-induced ILD.关键词
肺肿瘤/厄洛替尼/表皮生长因子受体Key words
Lung neoplasms/ Erlotinib/ Epidermal growth factor receptor分类
医药卫生引用本文复制引用
吴小玲,高广辉,任胜祥,周彩存..厄洛替尼致间质性肺病4例并文献复习[J].中国肺癌杂志,2012,15(8):494-498,5.
